Who Owns Protalix Biotherapeutics Inc (PLX)? 13F Institutional Holders (Q2 2026)

PLX ranks #4503 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

PLX is a disclosed holding of Jim Simons (Renaissance Technologies), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

104 institutions disclose a position in PLX, but none treat it as a major bet — even Main Street Financial Solutions, LLC, its most concentrated holder, allocates just 0.0% of its own portfolio to it.

BlackRock has added to its PLX position for two straight quarters, increasing it by $2.9M to reach $9.4M today.

Jane Street Group, LLC has trimmed its PLX position for two straight quarters, cutting it by $302.3K while still holding $219.5K.

PLX is down 0% today, but institutions show net buying of $7.0M this quarter — a divergence between today's price move and the underlying institutional flow.

PLX posted net income of $18.9M over the trailing twelve months, and currently trades at a P/E of 10.7.

• Profitable — net income of $18.9M over the trailing twelve months
• Revenue grew 30.1% year over year
• Net income improved year over year, from $6.3M to $18.9M
• Operating cash flow was negative, using $12.0M in cash
• Current ratio of 2.51x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.71x equity — within a conventional range